by Truveta staff | Jan 26, 2024 | Research
Truveta Research explored the rates of pediatric RSV immunizations and pediatric RSV-associated hospitalizations for children under the age of two. Of the 1,872,292 children under age two who were eligible to receive an RSV immunization, 3.7% of the eligible...
by Truveta staff | Jan 23, 2024 | Research
Overall, the rate of hospitalizations associated with respiratory viruses continues to increase (92.8% increase from November 2023 to the end of December 2023). The largest increases in hospitalizations over the past month were associated with influenza (251.7%...
by Truveta staff | Jan 23, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) have remained stable in the last 3 months, with rates in December 2023 about the same as rates in November 2023 and October 2023. For the anti-diabetic medications (ADMs), the number of...
by Truveta staff | Jan 18, 2024 | Research
Crohn’s disease, a complex chronic inflammatory disorder of the GI tract, affects approximately 780,000 Americans with an estimated 33,000 new cases diagnosed each year. Crohn’s, along with ulcerative colitis, are the two major forms of inflammatory bowel disease...
by Truveta Research | Jan 11, 2024 | Research, Research Insights
There is a complex relationship between cannabis use and mental health. We studied recent time trends of the rate of cannabis-induced disorder emergency department visits and cannabis-involved emergency department visits (both defined below). Between 2019 and 2020, we...
by Truveta Research | Nov 27, 2023 | Research, Research Insights
In the first comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data, Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15%...
